362 related articles for article (PubMed ID: 34427584)
21. VEXAS syndrome: A review of bone marrow aspirate and biopsies reporting myeloid and erythroid precursor vacuolation.
Cherniawsky H; Friedmann J; Nicolson H; Dehghan N; Stubbins RJ; Foltz LM; Leitch HA; Sreenivasan GM; Ambler KLS; Nevill TJ; McGinnis E; Wilson L; Beck DB; Chen LYC; Marcon KM
Eur J Haematol; 2023 Jun; 110(6):633-638. PubMed ID: 36788756
[TBL] [Abstract][Full Text] [Related]
22. Case Report: Genetic Double Strike: VEXAS and TET2-Positive Myelodysplastic Syndrome in a Patient With Long-Standing Refractory Autoinflammatory Disease.
Lötscher F; Seitz L; Simeunovic H; Sarbu AC; Porret NA; Feldmeyer L; Borradori L; Bonadies N; Maurer B
Front Immunol; 2021; 12():800149. PubMed ID: 35126364
[TBL] [Abstract][Full Text] [Related]
23. An update on VEXAS syndrome.
Al-Hakim A; Savic S
Expert Rev Clin Immunol; 2023 Feb; 19(2):203-215. PubMed ID: 36537591
[TBL] [Abstract][Full Text] [Related]
24. VEXAS syndrome: Clinical manifestations, diagnosis, and treatment.
Loeza-Uribe MP; Hinojosa-Azaola A; Sánchez-Hernández BE; Crispín JC; Apodaca-Chávez E; Ferrada MA; Martín-Nares E
Reumatol Clin (Engl Ed); 2024 Jan; 20(1):47-56. PubMed ID: 38160120
[TBL] [Abstract][Full Text] [Related]
25. VEXAS and Myelodysplastic Syndrome: An Interdisciplinary Challenge.
Kreutzinger V; Pankow A; Boyadzhieva Z; Schneider U; Ziegeler K; Stephan LU; Kübke JC; Schröder S; Oberender C; le Coutre P; Stintzing S; Jelas I
J Clin Med; 2024 Feb; 13(4):. PubMed ID: 38398362
[TBL] [Abstract][Full Text] [Related]
26. VEXAS Syndrome: A Novelty in MDS Landscape.
Templé M; Kosmider O
Diagnostics (Basel); 2022 Jun; 12(7):. PubMed ID: 35885496
[TBL] [Abstract][Full Text] [Related]
27. Accurate stratification between VEXAS syndrome and differential diagnoses by deep learning analysis of peripheral blood smears.
Chabrun F; Lacombe V; Dieu X; Geneviève F; Urbanski G
Clin Chem Lab Med; 2023 Jun; 61(7):1275-1279. PubMed ID: 36722042
[TBL] [Abstract][Full Text] [Related]
28. Clinical characteristics, disease trajectories and management of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome: a systematic review.
Kouranloo K; Dey M; Almutawa J; Myall N; Nune A
Rheumatol Int; 2024 Jul; 44(7):1219-1232. PubMed ID: 38129348
[TBL] [Abstract][Full Text] [Related]
29. Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry.
Comont T; Heiblig M; Rivière E; Terriou L; Rossignol J; Bouscary D; Rieu V; Le Guenno G; Mathian A; Aouba A; Vinit J; Dion J; Kosmider O; Terrier B; Georgin-Lavialle S; Fenaux P; Mekinian A;
Br J Haematol; 2022 Feb; 196(4):969-974. PubMed ID: 34651299
[TBL] [Abstract][Full Text] [Related]
30. Vacuoles in bone marrow progenitors: VEXAS syndrome and beyond.
Lacombe V; Hadjadj J; Georgin-Lavialle S; Lavigne C; Geneviève F; Kosmider O
Lancet Haematol; 2024 Feb; 11(2):e160-e167. PubMed ID: 38302223
[TBL] [Abstract][Full Text] [Related]
31. JAK inhibitors for the treatment of VEXAS syndrome.
Bindoli S; Baggio C; Doria A; Bertoldo E; Sfriso P
Exp Biol Med (Maywood); 2023 May; 248(5):394-398. PubMed ID: 37243340
[TBL] [Abstract][Full Text] [Related]
32. VEXAS syndrome: An update.
Khitri MY; Hadjadj J; Mekinian A; Jachiet V
Joint Bone Spine; 2024 Feb; 91(4):105700. PubMed ID: 38307404
[TBL] [Abstract][Full Text] [Related]
33. VEXAS syndrome: Clinical, hematologic features and a practical approach to diagnosis and management.
Koster MJ; Lasho TL; Olteanu H; Reichard KK; Mangaonkar A; Warrington KJ; Patnaik MM
Am J Hematol; 2024 Feb; 99(2):284-299. PubMed ID: 37950858
[TBL] [Abstract][Full Text] [Related]
34. Allogeneic stem cell transplantation as a curative therapeutic approach for VEXAS syndrome: a case report.
Loschi M; Roux C; Sudaka I; Ferrero-Vacher C; Marceau-Renaut A; Duployez N; Passeron T; Cluzeau T
Bone Marrow Transplant; 2022 Feb; 57(2):315-318. PubMed ID: 34999727
[TBL] [Abstract][Full Text] [Related]
35. The VEXAS Syndrome: Uncontrolled Inflammation and Macrocytic Anaemia in a 77-Year-Old Male Patient.
Himmelmann A; Brücker R
Eur J Case Rep Intern Med; 2021; 8(4):002484. PubMed ID: 33987129
[TBL] [Abstract][Full Text] [Related]
36. [VEXAS syndrome].
Zeeck M; Kötter I; Krusche M
Z Rheumatol; 2022 Nov; 81(9):782-786. PubMed ID: 35179640
[TBL] [Abstract][Full Text] [Related]
37. Adult-onset autoinflammation caused by somatic mutations in UBA1: A Dutch case series of patients with VEXAS.
van der Made CI; Potjewijd J; Hoogstins A; Willems HPJ; Kwakernaak AJ; de Sevaux RGL; van Daele PLA; Simons A; Heijstek M; Beck DB; Netea MG; van Paassen P; Elizabeth Hak A; van der Veken LT; van Gijn ME; Hoischen A; van de Veerdonk FL; Leavis HL; Rutgers A
J Allergy Clin Immunol; 2022 Jan; 149(1):432-439.e4. PubMed ID: 34048852
[TBL] [Abstract][Full Text] [Related]
38. Thrombotic manifestations of VEXAS syndrome.
Groarke EM; Dulau-Florea AE; Kanthi Y
Semin Hematol; 2021 Oct; 58(4):230-238. PubMed ID: 34802545
[TBL] [Abstract][Full Text] [Related]
39. [Two cases of VEXAS syndrome].
Gunnarsson K; Vivar Pomiano N; Tesi B; Tobiasson M; Creignou M; Ungerstedt J
Lakartidningen; 2022 Sep; 119():. PubMed ID: 36082915
[TBL] [Abstract][Full Text] [Related]
40. VEXAS syndrome: A review of cutaneous findings and treatments in an emerging autoinflammatory disease.
Saad AJ; Patil MK; Cruz N; Lam CS; O'Brien C; Nambudiri VE
Exp Dermatol; 2024 Mar; 33(3):e15050. PubMed ID: 38469984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
